Immune Targeting Systems
Latest round
- Series A
Last raised
- Feb 2010
Total raised
- $24M
Investors
- 4
About Immune Targeting Systems
Immune Targeting Systems, founded in 2003, is headquartered in London, UK. The company specializes in peptide-based therapeutics aimed at immune disorders. In February 2015, Immune Targeting Systems was acquired by Vaxin. The firm has completed a total of 6 deals, with its most recent deal occurring on February 17, 2015.Immune Targeting Systems is engaged in developing peptide-based therapeutics aimed at improving treatment outcomes for immune-related health issues.In 2021, Immune Targeting Systems reported a revenue of GBP 111,747.Immune Targeting Systems plans to expand its product portfolio by introducing new therapeutics in the coming years, although specific product release dates have not been disclosed.650 mn to support these initiatives. The financial support will bolster their research and development efforts, enhancing their capability to address immune-related disorders more effectively.
Who invested in Immune Targeting Systems
4 investors across 3 rounds
See all investors in Immune Targeting Systems
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immune Targeting Systems
Who invested in Immune Targeting Systems?
Immune Targeting Systems has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immune Targeting Systems raised?
Immune Targeting Systems has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immune Targeting Systems last raise money?
Immune Targeting Systems's most recent round on record is a Series A, in Feb 2010.
What does Immune Targeting Systems do?
Immune Targeting Systems, founded in 2003, is headquartered in London, UK.
Where is Immune Targeting Systems headquartered?
Immune Targeting Systems is headquartered in London, UK.
Which VCs invest in companies like Immune Targeting Systems?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Immune Targeting Systems's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immune Targeting Systems? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.